Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: I. In Vitro Pharmacological Characterization and Pharmacokinetic Properties

Kenneth J. Valenzano, Wendy Miller, Zhengming Chen, Shen Shan, Gregg Crumley, Sam F. Victory, Ellen Davies, Jin-Cheng Huang, Nezima Allie, Scott J. Nolan, Yakov Rotshteyn, Donald J. Kyle and Kevin Broglé
Journal of Pharmacology and Experimental Therapeutics August 2004, 310 (2) 783-792; DOI: https://doi.org/10.1124/jpet.103.063313
Kenneth J. Valenzano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Miller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhengming Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shen Shan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregg Crumley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sam F. Victory
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellen Davies
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jin-Cheng Huang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nezima Allie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott J. Nolan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yakov Rotshteyn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald J. Kyle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Broglé
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Mu opioid receptors are present throughout the central and peripheral nervous systems. Peripheral inflammation causes an increase in mu receptor levels on peripheral terminals of primary afferent neurons. Recent studies indicate that activation of peripheral mu receptors produces antihyperalgesic effects in animals and humans. Here, we describe the in vitro pharmacological and in vivo pharmacokinetic properties of a novel, highly potent, and peripherally restricted mu opioid agonist, [8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid (DiPOA). In a radioligand binding assay, DiPOA inhibited [3H]-diprenorphine binding to recombinant human mu receptors with a Ki value of ∼0.8 nM. The rank order of affinity for DiPOA binding to recombinant human opioid receptors was mu > kappa ≈ ORL-1 >> delta. DiPOA showed potent agonist effects in a human mu receptor guanosine 5′-O-(3-[35S]thio)triphosphate functional assay, with an EC50 value of ∼33 nM and efficacy of ∼85% {normalized to the mu agonist, [d-Ala2,MePhe4,Gly(ol)5]enkephalin}. Low potency agonist activity was also seen at ORL-1 and kappa receptors. DiPOA bound competitively to the opioid binding site of human mu receptors as demonstrated by a parallel rightward shift in its concentration-response curve in the presence of increasing concentrations of naltrexone. High and sustained (≥5 h) plasma levels for DiPOA were achieved following intraperitoneal administration at 3 and 10 mg/kg; central nervous system penetration, however, was ≤4% of the plasma concentration, even at levels exceeding 1500 ng/ml. As such, DiPOA represents a systemically available, peripherally restricted small molecule mu opioid agonist that will aid in understanding the role played by mu opioid receptors in the periphery.

Footnotes

  • DOI: 10.1124/jpet.103.063313.

  • ABBREVIATIONS: ORL-1, opioid receptor-like 1; CNS, central nervous system; DiPOA, [8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid; DAMGO, [d-Ala2,MePhe4,Gly(ol)5]enkephalin; GTPγ[35S], guanosine 5′-O-(3-[35S]thio)triphosphate; HEK-293, human embryonic kidney-293; DMSO, dimethylsulfoxide; P-gp, P-glycoprotein.

    • Accepted March 29, 2004.
    • Received December 15, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 310 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 310, Issue 2
1 Aug 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: I. In Vitro Pharmacological Characterization and P…
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: I. In Vitro Pharmacological Characterization and Pharmacokinetic Properties

Kenneth J. Valenzano, Wendy Miller, Zhengming Chen, Shen Shan, Gregg Crumley, Sam F. Victory, Ellen Davies, Jin-Cheng Huang, Nezima Allie, Scott J. Nolan, Yakov Rotshteyn, Donald J. Kyle and Kevin Broglé
Journal of Pharmacology and Experimental Therapeutics August 1, 2004, 310 (2) 783-792; DOI: https://doi.org/10.1124/jpet.103.063313

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: I. In Vitro Pharmacological Characterization and Pharmacokinetic Properties

Kenneth J. Valenzano, Wendy Miller, Zhengming Chen, Shen Shan, Gregg Crumley, Sam F. Victory, Ellen Davies, Jin-Cheng Huang, Nezima Allie, Scott J. Nolan, Yakov Rotshteyn, Donald J. Kyle and Kevin Broglé
Journal of Pharmacology and Experimental Therapeutics August 1, 2004, 310 (2) 783-792; DOI: https://doi.org/10.1124/jpet.103.063313
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Disease-Modifying Effects of Neurosteroids in Post-SE Models
  • Lacosamide and Rufinamide Against SE
  • A pediatric rat model of OP-induced status epilepticus
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics